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Introduction: Insulin is given by injection, because when administered orally, it would be
destroyed by enzymes in the digestive system, hence only about 0.1% reaches blood
circulation. The purpose of the present study was to use pH sensitive polyelectrolyte methyl
methacrylate (MMA)/itaconic acid (IA) nanogels as carriers in an attempt to improve
absorption of insulin administered orally.
Methods: Insulin (Ins) was incorporated into the MMA/IA nanogels (NGs) using the
polyelectrolyte complexation (PEC) method to form Ins/NGs-PEC. Several parameters,
including Ins:NGs ratio, pH, incubation time and stirring rate were optimized during
preparation of InsNGs-PEC. The prepared formulations were characterized in terms of
particle size (PS), polydispersity index (PdI), zeta potential (ZP) and percent entrapment
efficiency (% EE).
Results: The optimized InF12 nanogels had a PS, PdI, ZP and %EE of 190.43 nm, 0.186,
−16.70 mV and 85.20%, respectively. The InF12 nanogels were lyophilized in the presence
of different concentrations of trehalose as cryoprotectant. The lyophilized InF12 containing
2%w/v trahalose (InF12-Tre2 nanogels) was chosen as final formulation which had a PS,
PdI, ZP and %EE of 430.50 nm, 0.588, −16.50 mv and 82.10, respectively. The in vitro
release of insulin from InF12-Tre2 nanogels in the SGF and SIF were 28.71% and 96.53%,
respectively. The stability study conducted at 5±3°C for 3 months showed that lnF12-Tre2
nanogels were stable. The SDS-PAGE assay indicated that the primary structure of insulin in
the lnF12-Tre2 nanogels was intact. The in-vivo study in the diabetic rats following oral
administration of InF12-Tre2 nanogels at a dose of 100 IU/kg body weight reduced blood
glucose level significantly to 51.10% after 6 hours compared to the control groups.
Conclusions: The pH sensitive MMA/IA nanogels are potential carriers for oral delivery of
insulin as they enhanced the absorption of the drug.
Keywords: acrylic monomers, peptides self assembly, lyophilization, hypoglycemic effect,
polymeric nanogels
Introduction
Oral insulin delivery is still a dream of formulation scientists and the hope of diabetic
patients. Numerous attempts have been made, but with limited success and until now
there is no oral insulin formulation available on the market. The harsh conditions of the
stomach destroy orally administered insulin and only less than 0.1% reaches the blood
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circulation intact.1 Nano-formulations are generally used to
encapsulate drugs to limit their adverse effects and improve
bioavailability. However, in the case of encapsulating peptides
and proteins, the objectives are to retain the stability of loaded
peptides and proteins until delivered to the target organ.
Therefore, the nanocarriers with efficient loading capability
and preserving structural integrity of loaded peptides and pro-
teins are the key component of future research.2,3 In this con-
text, the oral peptide and protein deliveries via self-assembled
polyelectrolye nanocomplexes have shown great potential in
improving uptake of peptides and proteins, and also retaining
their biological activity.2,4–6 Oral administrations of insulin
encounter numerous barriers. The greatest oral barriers include
harsh environmental conditions of the stomach due to acid,
proteolytic enzymes and transport barriers due to intestinal
tight junctions. The encapsulation of peptides and proteins
such as insulin in carriers, namely polyacrylic acid (PAA)/
polymethacrylic acid (PMAA) and other carriers containing
carboxylic acid functional groups are promising strategy for
oral peptides and proteins deliveries. These materials are
reported as having absorption enhancement/proteolytic
enzyme inhibition capabilities.77,8
In the present study, pH sensitive polyelectrolyte
methyl methacrylate (MMA)/itaconic acid (IA) nanogels
(MMA/IA nanogels) were used to incorporate insulin
(Ins) because of the following reasons: 1) The com-
pounds have pH sensitive property, they show swelling
at basic pH and remained collapsed at acidic pH; 2)
Nanogels show an isoelectric point similar to peptides
and proteins; 3) Nanogels possess positive zeta potential
at pH below its isoelectric point and negative zeta poten-
tial above its isoelectric point. Thus, the MMA/IA nano-
gels are excellent candidates for the polyelectrolyte
complexation. The Insulin (Ins) was incorporated into
MMA/IA nanogels (NGs) using the polyelectrolyte com-
plexation (PEC) method to form a Ins/NGs-PEC formu-
lation. Thirteen Ins/NGs-PEC formulations were
prepared and several parameters were optimized includ-
ing 1) Ins:NGs ratios, 2) pH of the complex-forming
medium; 3) Incubation time for complexation; and 4)
Stirring rate of the complex-forming medium. The
effects of these parameters on the properties of formula-
tions such as the particle size (PS), polydispersity index
(PdI), zeta potential (ZP) and percent entrapment effi-
ciency (% EE) were evaluated. The optimized formula-
tion was subjected to in-vitro release study in the
simulated gastric fluid (SGF) and simulated intestinal
fluid (SIF). The optimized formulations were then
lyophilized using 0.5, 1, 2 and 3% w/v trehalose and
were evaluated for PS, PdI, ZP, %EE and in-vitro release
study. The morphology of Ins/NGs-PEC and lyophilized
lns/NGs-PEC formulations were analyzed by transmis-
sion electron microscope (TEM). The structural integrity
of insulin in the lyophilized Ins/NGs-PEC was assayed
using SDS-PAGE. The stability of lyophilized lns/NGs-
PEC formulations stored at temperatures of 5±3°C and
25±2°C (75±15%RH) were investigated. Finally, an in-
vivo study in diabetic rats was conducted to measure the
glucose levels in the animal model.
Materials
Methyl methacrylate (MMA), itaconic acid (IA), ethy-
lene glycol dimethacrylate (EGDMA), and benzoyl per-
oxide (BPO), were purchased from Sigma Aldrich (St
Louis, MO, USA). Tween 80 was purchased from Euro
Chemo-Pharma Sdn Bhd (Penang, Malaysia). The spec-
tra pore regenerated cellulose dialysis membrane hav-
ing MWCO 1000 Da was purchased from Nano Life
Quest Sdn Bhd (Selangor, Malaysia). Insulin aspart
solution (NovoRapid® 100 IU: 3.5 mg/Ml (Novo
Nordisk, Bagsvaerd, Denmark) was purchased from
the Pharmacy of Universiti Sains, Malaysia. Trehalose
and streptozotocin (STZ) were purchased from Sigma
Aldrich. A fast ultrafiltration kit (Amicon
Micropartition system MPS-1 Starter kit) was obtained
from W.R. Grace & Co. Danvers, MA, USA. The
Glucometer and strip used were the AccuChek
Performa (Hoffman-La Roche, Basel, Switzerland).
Methods
Preparation of MMA/IA nanogels
The pH-sensitive nanogels were prepared through free
radical polymerization according to the procedure
described by Mudassir et al 2017.9 Briefly the pH sensitive
polyelectrolyte was synthesized using methyl methacrylate
(MMA), Itaconic acid (IA) and crosslinker ethylene glycol
dimethacrylate (EGDMA), benzoyl benzoate and Tween
80 to form MMA/IA nanogels. EGDMA (1.5 mol%) was
added to MMA (70 mol%), while IA (30 mol%) was
dissolved in ethanol. Both solutions were mixed, then
benzoyl peroxide (BPO) 1% w/w) and Tween 80 (0.1%
w/v) were added. The mixture was heated to initiate poly-
merization and diluted with ethanol/water. The nanogels
dispersion was obtained by precipitating the mixture with
water.
Mudassir et al Dovepress
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Determination of the isoelectric point
(PI) of insulin, nanogels and Ins/NGs-PEC
using aqueous electrophoresis
(auto-titration)
The PI of insulin, nanogels and Ins/NGs-PEC was determined
using aqueous electrophoresis at pH range from 3.5 to 7.0.
Auto-titration was performed using a Malvern Zetasizer Nano
ZS instrument (Malvern Instruments Ltd, Malvern, UK) con-
nected to a MPT-1 auto-titrator (Malvern Instruments Ltd) as
accessory and operating via zetasizer nano software. Insulin
was dissolved in 10 ml distilled water at a concentration of
3 mg/ml. The pH of the insulin solution was automatically
adjusted by the titration unit through the addition of either 0.25
N, 0.025 N HCl or 0.25 N NaOH solution.
Preparation of Ins/NGs-PEC
The required amount of nanogel suspension was mixed
with an insulin solution in a universal glass bottle with
gentle magnetic stirring. Then, the pH of the mixture was
adjusted to 4.0 by adding either 0.2 N NaOH or 0.025
N HCl. Under these conditions, insulin and nanogels pos-
sessed positive and negative charge, respectively, which
led to the formation of Ins/NGs-PEC formulation by elec-
trostatic interaction between insulin and nanogel.
Thereafter, the Ins/NGs-PEC was incubated in an ice
bath with continuous magnetic stirring. Then, the Ins/NGs-
PEC was separated from free insulin using a fast ultrafil-
tration method. Briefly, 1 ml of prepared Ins/NGs-PEC
was placed in a centrifugal filter tube (Amicon
Micropartition System) and centrifuged at 4,000 rpm for
20 minutes to separate free and entrapped insulin in Ins/
NGs-PEC. The filtrate was collected and the amount of
insulin in the filtrate was quantified by the RP-HPLC
method.
The HPLC analysis was carried out using a Shimadzu
chromatic system with LC 20AD delivery pump (Kyoto,
Japan) and a phnomenex C18 column (150x4.6 mm). The
mobile phase consisted of 0.2 M sodium sulphate anhy-
drous (adjusted to pH 2.3 with ortho phosphoric acid) and
acetonitrile (74:26 v/v) with a flow rate of 1.2 ml/min. The
injection volume was 20 µl and detection wavelength was
set at 214 nm.
The amount of insulin associated with nanogels was
determined indirectly by measuring the difference between
the initial weight of insulin used in the formulation and the
amount of insulin recovered in the supernatant. The
amount of insulin in the supernatant was quantified using
HPLC. The percent entrapment efficiency (% EE) was
calculated using the following equation:
% EE ¼ Initial weight of InsulinWeight of free Insulin
Initial weight of Insulin
x 100
(1)
Measurement of particle size, polydispersity
index and zeta potential
Photon correlation spectroscopy (PCS) was used to deter-
mine particle size (PS) and polydispersity index (PdI) of
prepared Ins/NGs-PEC. Measurements were performed
using Zetasizer 1000HSA (Malvern Instruments). The
samples were diluted with filtered-distilled water pH 4
(0.45 μm membrane filter) to produce an appropriate
scattering intensity within 100–150 kilocounts
per second (kcps). The filtered-distilled water at pH 4
was used for dilution to prevent the swelling of nanogels
during measurement. The samples were measured in
triplicate.
Zeta potential (ZP) was measured using a Zetasizer
Nano series ZS from Malvern Instruments. The samples
were diluted with filtered-distilled water pH 4.0 (0.45
μm membrane filter) prior to the measurement to get
sample quality more than 1. Each sample was measured
in triplicate at 25°C with a minimum of 20 runs for each
sub-run.
Optimization of Ins/NGs-PEC parameters
The four parameters ratios of Ins:nanogel, pH, incuba-
tion time and stirring rate were optimized during pre-
paration of Ins/NGs-PEC formulations. The optimization
study was carried out by preparing 13 formulations
(InF1–InF13) as shown in Table 1. During optimization
only one parameter was varied at a time, while the other
three parameters were kept constant. The evaluated
responses were PS, PdI, ZP and%EE.
Lyophilization of optimized Ins/NGs-PEC
The optimized Ins/NGs-PEC formulations were lyophi-
lized in the presence of 0.5, 1, 2 and 3% w/v trehalose.
The required amount of Ins/NGs-PEC formulation was
mixed with trehalose and then frozen overnight at −20°C
prior to lyophilization. The frozen sample was lyophilized
using a freeze drying system (Labconco Corporation,
Kansas City, MO, USA) for 24 hours to allow complete
drying of samples.
Dovepress Mudassir et al
International Journal of Nanomedicine 2019:14 submit your manuscript | www.dovepress.com
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In-vitro release profiles of insulin from
optimized liquid and lyophilized Ins/
NGs-PEC formulations
The in vitro release studies were performed according to
USP specifications on the optimized liquid and lyophilized
Ins/NGs-PEC formulations. Simulated gastric fluid (SGF)
and simulated intestinal fluid (SIF) media without
enzymes were used. The Ins/NG-PEC formulation was
dispersed in 5 ml SGF (pH 1.2) and in 5 ml SIF (pH
6.8) media at 37±2°C and stirring rate of 100 rpm.
At predetermined time intervals (15, 30, 45 minutes, 1,
1.5, 2, 4, 6 and 8 hours), 300 µl of aliquots were with-
drawn and replaced with an equal volume of the same
fresh release media. The solution was centrifuged at
10,000 rpm for 10 minutes. The supernatant was collected
and subsequently filtered using a PTFE syringe filter
(Titan2®, Thermo Fisher Scientific, Waltham, MA,
Table 1 Optimization of Ins/NGs-PEC parameters
Formula
code
Parameter optimized Parameters kept constant
Ins:NGs
ratios
pHs Incubation
time (hrs)
Stirring
rate (rpm)
Ins:NGs
ratios
pHs Incubation
time (hours)
Stirring
rate (rpm)
InF1 1:20 - - - - 4.0 6 100
InF2 1:30 - - - - 4.0 6 100
InF3 1:40 - - - - 4.0 6 100
InF4 1:50 - - - - 4.0 6 100
Formulations InF1–InF4 were prepared using the following parameters: different ratios of Ins:NG, pH (4.0), incubation time (6
hours) and stirring rate (100 rpm). The best formulation was selected for further studies using different pHs (InF5–InF7)
InF5 - 1.2 - - Optimized
ratio
- 6 100
InF6 - 4.0 - - Optimized
ratio
- 6 100
InF7 - 7.4 - - Optimized
ratio
- 6 100
Formulations InF5–InF7 were prepared using the following parameters: different pHs, optimized Ins:NGs ratio, incubation time
(6 hours) and stirring rate (100 rpm). The best formulation was selected for further studies using different incubation time
(InF8–InF10)
InF8 - - 4 - Optimized
ratio
Optimized
pH
- 100
InF9 - - 6 - Optimized
ratio
Optimized
pH
- 100
InF10 - - 8 - Optimized
ratio
Optimized
pH
- 100
Formulations InF8–InF10 were prepared using different incubation times, optimized Ins: NGs ratio, optimized pHs and stirring rate
(100 rpm). The best formulation was selected for further studies using different stirring rate (InF11–InF13)
InF11 - - - 0 Optimized
ratio
Optimized
pH
Optimized incuba-
tion time
-
InF12 - - - 100 Optimized
ratio
Optimized
pH
Optimized incuba-
tion time
-
InF13 200 Optimized
ratio
Optimized
pH
Optimized incuba-
tion time
-
Formulation InF11–InF13 were prepared using different stirring rates, optimized Ins:NGs ratio, optimized pHs and optimized
incubation time. The best formulation was selected for further studies
Abbreviations: In or Ins, insulin; F, formulation; NGs, nanogels.
Mudassir et al Dovepress
submit your manuscript | www.dovepress.com
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USA), with 0.2 µm pore size. The amount of insulin
released from the Ins/NG-PEC was quantified by HPLC.
Fourier transform infrared (FTIR) spectra
The FTIR spectra of various samples, including insulin,
nanogels, trehalose, blank formulation lyophilized using
trehalose and optimized lyophilized Ins/NGs-PEC formu-
lation were recorded using a FTIR spectrometer (Nicolet
Nexus 470, Thermo Electron corporation, USA).
Evaluation of insulin primary structural
integrity in the lyophilized Ins/NGs-PEC by
SDS-polyacrylamide gel electrophoresis
(SDS-PAGE) assay
The primary structural integrity of insulin in optimized lyo-
philized Ins/NGs-PEC formulation was evaluated using
SDS-PAGE and was compared to the standard insulin
(Novorapid®) and protein marker. For this purpose, the insu-
lin, which was released from the optimized formulation at pH
6.8 was used for the assay. The resolving and stacking gels
were prepared using electrophoresis assembly (Mini-
PROTEIN 3 cell: Bio-Rad Laboratories Inc.,Hercules, CA,
USA). The 12% Tricine SDS-PAGE resolving gel and 5%
Tricine stacking gels were prepared. The 10 μL of insulin
sample was loaded on SDS-PAGE gel and run at a constant
voltage of 200 V (Power Pac; Bio-Rad) in running buffer for
1 hour. The staining and de-staining procedure were per-
formed to visualize the separated bands.
Transmission electron microscope (TEM)
The shape and morphology of the optimized liquid Ins/
NGs-PEC formulation and reconstituted lyophilized Ins/
NGs-PEC formulation were examined using a TEM
(CM12, FEI, Eindhoven, Netherland).
Stability study of lyophilized Ins/NGs-PEC
formulation
The stability study was performed on the optimized lyophi-
lized Ins/NGs-PEC formulation at two storage conditions (5
±3°C and 25±2°C) for 3 months. Stability of the formulation
was determined by evaluating PS, PdI, ZP and % drug
content and in vitro release of the stable formulation.
In-vivo evaluations
Animals
The in-vivo study was conducted using adult male SD rats.
The study was approved by the Animal Ethics Committee,
Universiti Sains Malaysia (USM/Animal Ethics Approval/
2014/(94) (585)) based on the USM’s guidelines for the
welfare of the animals “USM Guidelines for the Care and
Use of Animals for Scientific Purposes (2012).” The rats
were kept for 5 days in an animal transit room under the
photo-period schedule of 12 hours light/12 hours dark
prior to treatment to allow for acclimatization to the envir-
onment condition. Food and water were available ad libi-
tum. The study was conducted as follows:
Induction of diabetes using streptozotocin
(STZ)
Diabetes was induced by intra-peritoneal injection of STZ.
On experimental day one, the rats were kept fasting over-
night, but had free access to drinking water. STZ was dis-
solved in normal saline to a final concentration of 45 mg/ml
and was injected at the dose 45 mg/kg body weight. Rats
were returned to their cages, and given food and water for the
next 3–4 days till the induction of diabetes. The blood glu-
cose level was monitored using a blood glucose monitoring
system (AccuChek Performa, Hoffman-La Roche) by taking
samples from a rat tail vein. The rats showing fasting blood
glucose level ≥250mg/dL (13.7 mmol/L) were considered as
diabetic and were selected for the studies.
Study design
Diabetic rats weighing 180–220 g were randomly divided
into seven groups of six rats in each (n=6) (Table 2). The
rats were fasted overnight before starting the treatment.
Blood glucose level was measured at a pre-determined
time. The lyophilized lnsF12-Tre2 formulation was dis-
persed in the distilled water (pH 4) and administered orally
using a bulb tipped gavage needle. At the end of 8 hours
(T8) of the study period, the rats from control and the
treated groups were euthanized using pentobarbitone.
Measurement of blood glucose level
A single drop of blood sample was collected from rat tail
by a glucometer strip (AccuChek Performa, Hoffman-La
Roche) and blood glucose level was measured at predeter-
mined time intervals of 0 (immediately before receiving
treatment), 2, 4, 6 and 8 hours from the start of treatment.
The baseline level for each experimental group was the
mean value of blood glucose measured immediately before
treatment and was considered as 100%. Following the
treatments, the percentage glucose reduction at subsequent
time intervals was calculated from the baseline level.
Dovepress Mudassir et al
International Journal of Nanomedicine 2019:14 submit your manuscript | www.dovepress.com
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Statistical analysis
The Statistical Analysis was performed by one-way ANOVA.
For a significant difference, a post hoc Tukey’s HSD test was
performed.All data are presented asmean valueswith standard
deviations (mean ± SD). The differences were considered
statistically significant when p≤0.05. The analysis was done
using a statistical software IBM, SPSS version 22.
Results and discussion
Physical appearance and behavior of
insulin at different pHs
Visual appearance of insulin solutions at different pHs was
observed. Insulin solution was turbid between pH4.6 and
6.0, but clear below pH4.6 and above pH6.0 (Plate 1). This
behavior was due to the proteinacious nature of insulin (ie
presence of amino acid units). Amino acids possessed both
acidic and basic ionizable groups which could be charged
and uncharged depending upon the pH of the medium.
However, at particular pH values the protein possessed
no charge, which is referred to as the isoelectric point
(PI). At pH near its PI, proteins tend to aggregate and
show minimum solubility.10
Formation of Ins/NGs-PEC
The polyelectrolyte complexation phenomenon was adopted
to develop Ins/NGs-PEC in order to avoid damage to insulin.
The interactions between insulin and polyelectrolyte nano-
gels are predominantly of electrostatic nature. This charac-
teristic allows insulin to bind to polyanions at pH below PI
(pH<PI) and polycations at pH above PI (pH>PI). The PI of
insulin and nanogels were investigated using aqueous elec-
trophoresis and the results are presented in Figure 1A and
B. The curve of aqueous electrophoresis for insulin showed
that the ZP of insulin changed from positive to negative as
the pH was increased from 3.5 to 7 with the point of net zero
charge (PI) observed around pH 4.8. Similarly, the curve of
aqueous electrophoresis for nanogels also showed that the ZP
of nanogels changed from positive to negative as the pH was
increased from 1.5 to 7 with point of net zero charge (PI)
observed around pH 2.78.
The PEC formation (Ins/NGs-PEC) was confirmed
using the following two techniques, by measuring 1)
The PI of lns/NGs-PEC; and 2) The ZP of lns/NGs-
PEC. In the first technique, PI of Ins/NGs-PEC was
determined using aqueous electrophoresis and compared
Table 2 Treatments received by diabetic rat groups for determination of blood glucose level
Groups Codes Design of treatment Treatments No. of rats
Control-I Wpo Water (per oral) Free access 6
Control-II BFpo Blank formulation (per oral) Equivalent wt. to 100 IU/kg body weight 6
Control-III Ipo NovoRapid®
(per oral)
Insulin solution 100 IU/kg body weight 6
Control-IV Isc (NovoRapid®) (subcutaneous) 5 IU/kg body weight 6
Test-V NGI 25IU po Ins-loaded-NGs (per oral) 25 IU/kg body weight 6
Test-VI NGI 50IU po Ins-loaded-NGs (per oral) 50 IU/kg body weight 6
Test-VII NGI po 100IU Ins-loaded-NGs (per oral) 100 IU/kg body weight 6
Abbreviations: Wpo, water per oral (po); BFpo, Blank Formulations (po); Ipo, insulin (po); Isc, insulin (sc); NGI 25 po, InF12-Tre2 containing insulin 25 IU (po); NGI 50 po,
InF12-Tre2 containing insulin 50 IU (po); NGI 100 po, InF12-Tre2 containing insulin 100 IU (po).
Plate 1 Physical appearance of insulin solution at different pH values.
Mudassir et al Dovepress
submit your manuscript | www.dovepress.com
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with PI of free insulin. The PI of Ins/NGs-PEC is pre-
sented in Figure 1C. The results show the PI of Ins/
NGs-PEC at 3.69 pH, while the PI of free insulin at
4.81pH. Changing of the PI value indicated the forma-
tion of PEC between insulin and nanogels. A similar
finding was reported by Schmittet al11 whereby the
authors observed the PI value was changed following
complex formation between β-lactoglobulin and acacia
gum. In the second technique, the ZP value of Ins/NGs-
PEC was compared with the ZP values of free insulin
and free nanogels. The ZP value of free insulin, free
nanogels and Ins/NGs-PEC at pH 4 were 12.60±0.62
mV, −43.17±1.81 mv and −16.77±0.50 mV, respectively.
Thus, formation of complexation between insulin and
nanogels had caused a decrease in the negative charge
value of ZP from −43.17±1.81 mV to −16.77±0.50 mV
at pH 4.0. This was expected because insulin had the net
positive ZP (12.60±0.62 mV) at pH 4.0. Under this
condition, the electrostatic attraction between insulin
and nanogels would occur. Thus, insulin had offset the
negative charge of nanogels, and consequently changed
the ZP to less negative value. A similar observation was
reported by Luo et al12 in the investigation of α-
tocopherol/zein-chitosan (TOC/zein–CS) nanoparticles.
In another study, Fan et al,13 indicated the successful
layer-by-layer (LbL) deposition of Poly(α-β-L-malic
acid) (PMA) and water-soluble chitosan (WSC) on the
insulin particles by observing the shifting of ZP from
positive to negative.
Optimization of Ins/NGs-PEC
Table 3 Shows the influence of Ins:NGs ratios, pH, incu-
bation time and stirring rate on PS, PdI, ZP and % EE of
the Ins/NGs-PEC.
Effect of Ins:NGs ratios
InF1, InF2, InF3 and InF4 formulations were prepared
using lns:NGs ratios of 1:20, 1:30, 1:40 and 1:50,
respectively. The other parameters were kept constant
and set as follows: pH 4, incubation time of 6 hours
and stirring rate of 100 rpm. It was observed that PS
and PdI were significantly higher (p<0.05), while ZP
and %EE were significantly lower (p<0.05) at Ins:NGs
ratios of 1:20 (lnF1) than 1:30 (lnF2) and 1:40 (lnF3).
The PS was out of nano range and the PdI value was 1.
The possible reason for higher PS and PdI of InF1
might be due to its ZP being low (−9.05±0.153 mV),
which may cause aggregation of particles. However,
there were no significant changes (p>0.05) in PS, PdI,
ZP and %EE when the Ins:NGs ratio was further
increased from 1:40 (InF3) to 1:50 (InF4). Nam et al14
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Figure 1 Determination of the isoelectric point in (A) Insulin, (B) Nanogels, and (C) Ins/NGs-PEC. Mean ± SD, n=3.
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also reported similar findings in the insulin-loaded nano-
particles through the polyelectrolyte complex formation
using low molecular weight water soluble chitosan
(LMWSC). They found the particle size increased,
according to the amount of insulin incorporated.
The ZP-value of Ins/NGs-PEC can be negative or
positive depending upon the dominant component of the
polyelectrolyte complex (insulin or nanogels). All the for-
mulations (InF1, InF2, InF3 and InF4) prepared at differ-
ent Ins:NGs ratios were found to have a negative charge of
ZP. This could be due to the contribution of negative
charge from nanogels exceeding the positive charge of
insulin at the investigated Ins:NGs ratios of 1:20, 1:30,
1:40 and 1:50. A similar finding was reported by Lin et al15
in the investigation of nanoparticles prepared using chit-
osan/γ-glutamic acid (CS/γ-PGA) at a ratio of 4.5:1.0 (w/
w). They observed at the weight ratio used, the formula-
tion had a positive charge of ZP. This is because at this
ratio the positively charged CS was significantly higher
than the negatively charged γ-PGA.
Therefore, based on the results of PS, PdI, ZP and %
EE, the Ins:NGs ratio of 1:40 (InF3) was found to be
optimum and this ratio was used for further studies in
the optimization of pH.
Effect of pH
InF5, InF6 and InF7 formulations were prepared at different
pHs of 1.2, 4.0 and 7.4, respectively. Other parameters such
as lns:NGs ratio of 1:40, incubation time of 6 hours, stirring
rate of 100 rpm were kept constant. The PS and PdI of lnF5
formulation prepared at pH 1.2 were significantly higher
(p<0.05), than InF6 prepared at pH 4.0. While the ZP and
% EEwere significantly lower compared to lnF6 formulation
prepared at pH 4.0. Bigger PS at pH 1.2 could be due to the
binding of the aggregated protein onto anionic polymers
(nanogels) in the acidicmedium.16,17 Another possible expla-
nation for the increase in PS at pH 1.2 is based on aggrega-
tion of nanogels at pH below its pKa value. However, further
increasing the pH from 4.0 to 7.4 had no significant effect
(p>0.05) on PS, but PdI and %EE were decreased
Table 3 Effect of Ins/NG ratios, pH, incubation times and stirring rates on Ins/NGs-PEC properties
Effect of Ins:NGs ratios on the Ins/NGs-PEC properties
Formulation code Ins:NGs PS (nm) PdI ZP (mV) % EE
InF1 1:20 1399±55.59 1±0 −9.05±0.15 66.22±3.16
InF2 1:30 235.4±5.80 0.318±0.025 −16.00±0.65 75.02±3.31
InF3 1:40 190.4±0.90 0.186±0.023 −16.70±0.50 85.20±2.33
InF4 1:50 186.2±4.00 0.173±0.021 −15.70±0.28 82.45±3.06
Effect of pH on the Ins/NGs-PEC properties
pH PS (nm) PdI ZP (mV) % EE
InF5 pH 1.2 8299.70±1156.20 1.000±0.00 1.38±1.06 78.50±1.50
InF6 pH 4.0 190.40±0.90 0.186±0.023 −16.70±0.50 85.20±2.33
InF7 pH 7.4 186.20±4.24 0.145±0.028 −48.60±0.50 18.42±5.06
Effect of incubation time on the Ins/NGs-PEC properties
Incubation time (hours) PS (nm) PdI ZP (mV) % EE
InF8 4 188.13±1.95 0.133±0.01 −23.43±0.64 76.44±1.97
InF9 6 190.40±0.90 0.186±0.023 −16.70±0.50 85.20±2.33
InF10 8 191.03±1.10 0.145±0.04 −16.20±1.20 82.42±1.13
Effect of stirring rate on the Ins/NGs-PEC properties
Stirring rate (rpm) PS (nm) PdI ZP (mV) % EE
InF11 0 249.10±4.12 0.294±0.04 −21.80±1.08 75.28±1.63
InF12 100 190.40±0.90 0.186±0.023 −16.70±0.50 85.20±2.33
InF13 200 189.33±1.74 0.151±0.035 −22.50±0.90 75.71±4.62
Abbreviations: Ins, Insulin; NGs, Nanogels; PEC, Polyelectrolyte complex; InF, Insulin loaded formulations; PS, Particle size; PdI, Polydispersity index; ZP, Zeta potential; %
EE, Percentage entrapment efficiency.
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significantly (p<0.05), while the negative charge of ZP
increased significantly (p<0.05) from −16.70±0.50 mV
(InF6) to −48.60±0.50 mV(InF7).
The driving force for the complexation of insulin and
nanogel was mainly due to hydrophobic interaction. Lower
%EE at pH 1.2 (below PI of insulin and nanogels), could
be due to both insulin and nanogel possessing positive
charges and repelling each other. While higher %EE at
pH 4.0 (below the PI of insulin), could be due to insulin
exhibiting a positive charge and interacting with nega-
tively charged carboxyl functional groups of nanogels. At
pH 7.4 (above PI of insulin and nanogels), both insulin and
nanogel possess negative charges and repel each other,
hence they had lower %EE. Among the formulations stu-
died lnF6, which was prepared at pH 4 had the best
characteristics of PS, PdI, ZP and %EE. Thus, pH 4.0
was selected for further study in the optimization of the
incubation time.
Effect of incubation time
InF8, InF9 and InF10 formulations were prepared at incu-
bation times of 4, 6 and 8 hours, while other parameters,
such as lns:NGs ratio of 1:40, pH 4 and stirring rate of 6
hours, were kept constant. There was no significant differ-
ence (p>0.05) in the PS, but PdI and %EE were signifi-
cantly increased, while the negative charge of ZP was
significantly decreased (p<0.05) when incubation time
was increased from 4 to 6 hours. However, there was no
significant change (p>0.05) in PS, ZP and %EE when
incubation time was prolonged from 6 to 8 hours.
Therefore, based on the results obtained the
6-hour incubation period used to prepare the InF9 formu-
lation was considered optimum and was selected for
further studies in the optimization of the stirring rate.
Effect of stirring rate
InF11, InF12 and InF13 formulations were prepared at
a stirring rate of 0, 100 and 200 rpm, respectively. Other
parameters including ln:NGs ratio of 1:40, pH 4 and
incubation time of 6 hours were kept constant. The PS,
PdI and ZP were decreased significantly (p<0.05) but the
%EE was increased significantly (p<0.05) when the
strrring rate was increased from 0 to 100 rpm. Increasing
the stirring rate further to 200 rpm did not significantly
(p>0.05) reduce the PS, but decreased the PdI and %EE
significantly (p<0.05), while the ZP increased significantly
(p<0.05). The possible influences of a stirring rate could
be explained as follows: Deposition of insulin on nanogel
surface was facilitated at a stirring rate of 100 rpm. At this
stirring rate, the insulin molecules could reach the absorp-
tion surface of nanogels rapidly and interact electrostati-
cally, hence resulting in a higher %EE. However, the %
EE was lower when the stirring rate was increased to
200 rpm. This could be due to the faster agitation of the
solution causing the loosely bound insulin molecules on
the nanogels surface to detach, hence less formation of
a complex between insulin and nanogel. A similar finding
was observed at a stirring rate of 0 rpm (without stirring),
whereby the %EE were also low which could be due to the
longer time needed to reach equilibrium for deposition of
insulin on the nanogels surface. Thus, based on these
findings, the InF12 formulation prepared at a stirring rate
of 100 rpm, lns: NGs ratio of 1:40, pH 4 and incubation
time of 6 hours were selected for further study.
Lyophilization study
Lyophilization is a commonly used technique to improve
stability during storage by converting a colloidal formula-
tion into a solid preparation. However, during the lyophi-
lization process, the preparation encountered various
stresses. Therefore, a cryoprotectant such as trehalose is
usually used to protect the sample during lyophilization
process. The lnF12 formulation was lyophilized in the
presence of 0.5, 1, 2 and 3% w/v trehalose and the for-
mulations were given codes InF12-Tre0.5, InF12-Tre1,
InF12-Tre2 and InF12-Tre3, respectively. The results of
Table 4 Lyophilization of InF-12 formulation using trehalose as a cryoprotectant. Mean ± SD, n=3
Trehalose (% w/v) Formulation code PS (nm) PdI ZP (mV) % EE
0% InF12 NM NM NM NM
0.5 InF12Tre0.5 NM NM NM NM
1 InF12Tre1 893.90±56.29 1.000±0.000 −27.43±1.89 74.57±4.08
2 InF12Tre2 430.50±27.61 0.588±0.094 −16.50±0.60 82.10±2.12
3 InF12Tre3 418.73±55.38 0.459±0.228 −15.80±0.67 80.71±2.89
Abbreviations: Tre, Trehalose; InF, Insulin loaded formulations; PS, Particle size; PdI, Polydispersity index; ZP, Zeta potential; % EE, Percentage entrapment efficiency; NM,
Not measured.
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PS , PdI, ZP and % EE are presented in Table 4. Before
lyophilization the lnF12 formulation had a PS, PdI, ZP and
%EE of 190.4±0.90 nm, 0.186±0.023, −16.70±0.50 mV,
and 85.20±2.33, respectively. Lyophilization of the lnF12
formulation without trehalose caused its particles to col-
lapse, aggregate and strongly stick to the wall of the tube
and upon reconstitution the formulation (InF-12) could not
be redispersed. Similar results were also observed when
0.5% w/v trehalose was used during lyophilization of
InF12-Tre0.5. Thus, the PS, PDI, ZP and %EE of the
formulations (InF12 and InF12-Tre0.5) could not be mea-
sured. However, increasing the trehalose concentration
from 0.5 (InF12-Tre0.5) to 1 (InF12-
Tre1), 2 (InF12-Tre2) and 3%w/v (InF12-Tre3) had pro-
duced free flowing particles, and after reconstituting the
formulations were easily redispersed. The PS of the for-
mulations (InF12-Tre1, InF12-Tre2 and InF12-Tre3) were
increased significantly (p<0.05) in comparison to PS of
lnF12 before lyophilization, but the PS was still in the
nano range. Increasing of PS could be due to aggregation
of particles during lyophilization process. Among the con-
centrations of trehalose used during lyophilization, 2 w/v%
(InF12-Tre2) was considered the optimum as increasing
the concentration to 3 w/v% (InF12-Tre3) did not improve
the characteristics of the formulation. Therefore, InF12-
Tre2 which had a PS, PDI, ZP and %EE of 430.50±27.61,
0.588±0.094, −16.50±0.60 and 82.10±2.12, respectively
was chosen as an optimized formulation for further
investigation.
In-vitro release study
The release profiles of insulin from the liquid formulation
of InF12 and lyophilized formulation of InF12-Tre2 in
the simulating gastric fluid (SGF) at pH 1.2 and intestinal
fluid (SIF) at pH 6.8 are presented in Figure
2A and B, respectively. There were no significant
differences (p>0.05) in the insulin release from InF12
(32.45±3.88%) and InF12-Tre2 (28.94±3.48%) formula-
tions in the SGF medium up to 8 hours (Figure 2A and
B). The retardation of insulin release at pH 1.2 in both
formulations might be due to the fact that the nanogel did
not swell and formed tight shrunken (un-swollen) nano-
gel network in highly acidic media. This hindered the
diffusion and resulted in lower release of insulin from
both formulations in the acidic medium. Another reason
could be the involvement of hydrophobic interaction as
dominating factor which facilitated strong binding and
attachment of insulin and nanogels at acidic pH.18,19 In
contrast, the release of insulin from InF12 and InF12-Tre
2 formulations in SIF (at pH 6.8) were rapid. In the first
15 mins, InF12 formulation released a significantly
higher (p<0.05) percentage of insulin (80.46±5.01%)
than the InF12-Tre2 formulation (63.55±5.52%) (Figure
2A and B). However, there were no significant
differences (p<0.05) in the total percentage of insulin
release from lnF12 (91.43±4.50%) and InF12-Tre2
(96.53±4.95%) formulations at the end of 8 hours. The
possible reasons for the rapid insulin release from both
formulations in the SIF (pH 6.8) could be due to the
swelling, diffusion and erosion process.20 At basic and
neutral pH, nanogels showed higher swelling due to ioni-
zation of carboxylic groups. As nanogels swelled to the
maximum capacity, the erosion of nanogel networks was
initiated, which facilitated the release of entrapped drugs.
Cui et al21 reported similar findings for the in-vitro
release of insulin from carboxylated chitosan grafted
poly (methyl methacrylate) nanoparticle (CCGN). They
observed a slow release rate of insulin at pH 2, but a fast
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Figure 2 In-vitro release of insulin from (A) Liquid formulation of InF-12, and (B)
Lyophilized formulation of InF12-Tre2 in SGF (pH 1.2) and SIF (pH 6.8) at 37°C.
Mean ± SD, n=3.
Abbreviations: SGF, Simulated gastric fluid; SIF, Simulated intestinal fluid.
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release rate at pH 6.8 and pH 7.4. In another study,
Karnoosh-Yamchi et al22 reported the in vitro insulin
release from N-iso-propylacrylamide-methacrylic acid-
hydroxy ethyl methacrylate (NIPAAm–MAA–HEM)
nanohydrogel was lower at pH 1.2 and higher at pH 6.8.
FTIR spectra
The FTIR spectra of A) insulin, B) nanogels, C) trehalose, D)
lyophilized blank formulation containing trehalose, and E)
InF12-Tre2 formulation is presented in Figure 3. The insulin
shows a characteristic broad peak at 1649 cm–1.23 The FTIR
spectra of nanogels shows increased peak intensity of the C=O
group at 1731.49 cm–1 whichwas associated with the presence
of the additional C=O groups from itaconic acid. Additionally,
the spectra also show a broader peak in the range of
3700–3100 cm–1which suggested theOH stretching vibrations
of carboxylic groups of itaconic acid. The FTIR spectrum of
InF12-Tre2 formulation showed the characteristic peaks of
nanogels and insulin had shifted, which indicated that the
insulin was encapsulated in the nanogels network.24
Evaluation of insulin integrity
Insulin may be degraded/or undergo aggregation during
encapsulating procedures and within the microenviron-
ment of nanocarriers.25 SDS-PAGE provides information
on the primary structural integrity of proteins. Therefore,
the structural integrity of insulin in InF12-Tre2 was
assayed using SDS-PAGE. Figure 4 shows the SDS-
PAGE analysis of a marker (unstained low molecular
weight ranges protein ladder) in lane 1, insulin released
from InF12-Tre2 (in PBS at pH 6.8) in lane 2 and standard
insulin (Novorapid®) in lane 3. The results revealed that
standard insulin and insulin released from InF12-Tre2
travelled to the same level of 5.8 kDa, compared to the
unstained standard protein ladder. Moreover, no lower or
higher band was observed in lane 2, which indicated the
absence of degradation product or formation of aggregated
product in the SDS-PAGE analysis. These findings sug-
gested that the structural integrity of insulin was preserved
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Figure 3 FTIR spectra of (A) Insulin, (B) Nanogels, (C) Trehalose, (D) Lyophilized blank formulation, and (E) Lyophilized InF12-Tre2.
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Figure 4 SDS-PAGE results. Lane 1: Unstained low range protein ladder; Lane 2:
Insulin released from formulation; Lane 3: Standard insulin.
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in the lyophilized formulation (InF12-Tre2). Similar find-
ing was also reported by Alibolandi et al26 using SDS-
PAGE assays to show the structural integrity of loaded
insulin. In another study, Hurkat et al27 also used SDS-
PAGE to confirm the stability of loaded insulin in the
amphiphilic copolymers of dextran (DEX) 5000–poly (lac-
tic-coglycolic acid) (PLGA).
TEM examination
The TEM images in Figure 5 revealed that the particle of
InF12 formulation had spherical shape and the size was
<200 nm. However, the reconstituted InF12-Tre2 formula-
tion displayed irregular shape and PS was increased, but it
was still in the nano range (<500 nm).
Stability study
The InF12-Tre2 formulations stored at 5±3°C and 25±2°C
/75±15%RH were observed visually. The flow ability as
well as the ease of re-dispersion of InF12-Tre2 formula-
tion stored at 5±3°C was preserved up to 3 months of the
study period. However, the InF12-Tre2 formulations
stored at 25±2°C/75±15%RH became sticky and aggrega-
tion of particles was seen after 1 month storage.
The PS, PdI, ZP of InF12-Tre2 formulation stored at
5±3°C and 25±2°C/75±15%RH were measured for 3
months, and the results are presented in Table 5. There
was no significant (p>0.05) change in the PS, PdI, ZP
and %drug content of the InF12-Tre2 samples stored at
5±3°C during the 3-month study period. However, after
1 month of the stability study the PS and PdI of the
InF12-Tre2 samples stored at 25±2°C/75±15%RH were
not measured because the samples were sticky and the
particles aggregated. The aggregation of particles may
be induced by hydrophobic polymer-protein interaction,
which occurred during storage at room temperature.28,29
The drug content was reduced and ZP was increased
significantly (p>0.05). The decrease in the % insulin
content of the InF12-Tre2 formulation stored at room
temperature could be due to degradation of insulin by
deamidation and dimer formation.30,31
In-vitro release study of formulation
stored at 5±3°C
The in-vitro release profiles of insulin from the InF12-Tre2
formulation stored at 5±3°C in SGF and SIF at T0M, T1M,
T2M and T3M are presented in Figure 6A and B. There was
no significant (p>0.05) difference in the % insulin release in
SGF and SIF during the 3-month study period. These results
suggested that the InsF12-Tre2 formulation stored at 5±3°C
was stable throughout the study period.
1000 nm 500 nm
Figure 5 TEM of (A) InF12 before lyophilization and (B) Reconstituted lyophilized
InF12-Tre2 after lyophilization.
Table 5 The stability data of InF12-Tre2 formulation stored at 5±3°C and 25±2°C/75±15%RH. Mean ± SD, n=3
Temperature: 5±3°C
Parameters T0M T1M T2M T3M
PS (nm) 430.5±27.60 425.53±30.03 411.96±22.78 421.13±24.00
PDI 0.588±0.094 0.546±0.053 0.400±0.180 0.422±0.052
ZP (mV) −16.50±0.60 −16.73±0.64 −17.60±0.964 −16.60±0.781
Drug content (%) 100.28±3.91 97.44±3.79 98.76±4.71 98.26±4.34
Temperature: 25±2°C/75±15%RH
Parameters T0M T1M T2M T3M
Particle size (nm) 430.5±27.60 NM NM NM
PDI 0.588±0.094 NM NM NM
Zeta potential (mV) −160.50±0.60 −22.63±1.59 −26.33±1.16 −34.70±0.50
Drug content (%) 100.28±3.91 82.49±3.68 68.17±3.15 51.39±4.59
Abbreviations: T0M, Time at zero month (immediately after preparation); T1M, Time at one month; T2M, Time at two months; T3M, Time at three months; InF, Insulin
loaded formulations; PS, Particle size; PdI, Polydispersity index; ZP, Zeta potential; % EE, Percentage entrapment efficiency; RH, Relative humidity; NM, not measured.
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In-vivo evaluations
Determination of blood glucose level
The effect of InF12-Tre2 formulation on blood glucose
level of diabetic rats is summarized in Figure 7. The
percentage reduction in blood glucose was considered as
evidence of insulin absorption. The response to orally
administered InF12-Tre2 formulation was presented by
plotting the percentage of blood glucose reduction from
initial blood glucose level (100%) vs time. The rat’s blood
glucose measured just before starting of the treatment (at
time=0) was considered as initial blood glucose level and
was taken as 100%. Subsequent percentage of blood glu-
cose reduction was measured at predetermined time inter-
vals of 2, 4, 6 and 8 hours. Control groups were treated
with water per oral (Wpo), blank formulation per oral
(BFpo) and insulin solution per oral (Ipo) for comparison
with the oral doses of InF12-Tre2 formulation. There was
no significant difference (p>0.05) in the blood glucose
level among the three control groups (Wpo, BFpo and
Ipo) up to the end of the 8-hour study period. Therefore,
the administration of blank formulation per oral (BFpo)
and insulin solution per oral (Ipo) had no effect on blood
glucose level and the response was similar to the control
group treated with water per oral (Wpo). The details of
control and experimental groups are presented in Table 2.
Subcutaneous insulin injection (Isc) at the dose of 5IU/
kg was also administered as control to observe an acute
and rapid hypoglycemic effect of insulin. The subcuta-
neous administration of insulin (Novorapid®) showed the
blood glucose level reduced to 14.67±4.24% within 2
hours of administration. At 8 hours after subcutaneous
injection, the hypoglycemic effect of insulin was
decreased, and hence the blood glucose level returned to
47.50±8.70%. These results suggested that the
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Figure 7 Effect of oral administration of the three doses (25, 50 and 100 IU/kg body weight) of lnF12-Tre2 and four control groups on the percentage reductions in blood
glucose level in the streptozotocin-induced diabetic rats.*Statistically significant difference to BFpo. Mean ± SD, n=6. Data points represent relative values of the initial blood
glucose concentration.
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oral; NGI 50 po, InF12-Tre2 containing insulin 50 IU per oral; NGI 100 po, InF12-Tre2 containing insulin 100 IU per oral.
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subcutaneous injection significantly (p<0.05) reduced the
blood glucose level of diabetic rats compared to the three
control groups (Wpo, BFpo and Ipo) within 2 hours.
Among the three doses of InF12Tre2 nanogels, 50 and
100 IU/kg (NGI 50po and NGI 100po) had the stronger
hypoglycemic effect within 6 hours compared to control
groups (Wpo, BFpo and Ipo). The blood glucose level was
considered 100% at the start of the experiment. The blood
glucose level after 6 hours was decreased significantly
(p<0.05) to 81.50±6.86% and 51.10±5.50% following
oral administration of NGI 50po and NGI 100po, respec-
tively. However, there were no significant differences
(p>0.05) in the blood glucose levels of NGI 50 po (79.30
±5.41%) and NGI 100po (63.00±8.00%) measured at 8
hours compared to 6 hours. Administration of 25 IU/kg
dose (NGI 25po) had not reduced the blood glucose level
significantly (p>0.05) over the same study period of 8
hours. These results revealed that the oral InF12-Tre2
nanogels showed a dose-dependent hypoglycemic effect.
The reduction of blood glucose level in the diabetic rats
suggested the release of insulin from InF12-Tre2 nanogels
in the small intestine was in accordance with the finding in
the in-vitro release study. The results also reflected appre-
ciably increased in insulin absorption by the lnF12-Tre2
nanogels. Mukhopadhyay et al32 also showed reduction in
blood glucose levels following oral administration of chit-
osan/insulin nanoparticles at doses of 50 and 100 IU/kg
body weight. In another study Sarmento et al19 investi-
gated the oral insulin-loaded alginate/chitosan nanoparti-
cles at doses of 25, 50 and 100 IU/kg body weight. The
authors reported faster blood glucose level reduction at the
dose of 100 as compared to 50 and 25 IU/kg body weight.
The results of blood glucose suggested that the InF12-
Tres nanogels had improved insulin absorption administered
orally. This was probably through the following mechan-
isms: 1) pH-responsive behavior of nanogel might have
protected insulin from degradation in the acidic environment
of GIT; 2) Carboxylic acid functional group in the nanogel
might have deactivated the proteolytic enzymes to protect
insulin from degradation by digestive enzymes in GIT; and
3) Carboxylic acid functional groups in the nanogels might
have opened the intestinal tight junctions to facilitate the
paracellular transport of insulin.33
Conclusions
The pH sensitive MMA/IA polyelectrolyte nanogels were
used as carriers to deliver insulin orally. Insulin was
entrapped in the nanogels by using the PEC method. The
final formulation of lyophilized lnF12-Tre2 nanogels was
successfully developed and optimized. The particle size of
the nanogels was in the nano range. The SDS-PAGE assay
revealed that the insulin structure in lnF12-Tre2 nanogels
was still intact. The lnF12-Tre2 nanogels were stable at 5
±3°C storage condition during the 3-month stability study.
The oral administration of InF12-Tre2 nanogels to diabetic
rats had reduced the blood glucose significantly.
Therefore, it is suggested that the oral ln12-Tres2 nanogels
have the potential to be used as an alternative route for
delivery of insulin.
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